IDEAYA Biosciences, Inc.
IDYA
Positions held
Your positionsIDYA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- IDEAYA Biosciences is positioned in a competitive biotechnology sector with a strong focus on innovative therapies, which could lead to significant market opportunities.
- Revenue increased by 35% compared to the prior quarter, reaching $8.9 million.
- The company has a current ratio of 10.451, indicating strong liquidity and the ability to cover short-term liabilities.
- The biotechnology industry is facing regulatory challenges that could impact the approval timelines for new therapies, affecting IDEAYA's growth potential.
- The operating margin remains significantly negative at -1380.7%, indicating ongoing operational inefficiencies.
- The company reported a net income loss of $112.452 million in the latest quarter, reflecting ongoing financial struggles.
Fundamentals
| Market cap | $3.48B | Enterprise value | $2.68B | Trailing P/E | — | Forward P/E | -9.00 |
| PEG | — | Price / book | 2.90 | Beta | -0.04 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | -59.7% | Operating margin | -13.8% |
| Profit margin | -74.8% | ROE | -16.2% | ROA | -11.5% | Debt / equity | 0.02 |
| Current ratio | 10.45 | Free cash flow | -$70.85M | Analyst recommendation | strong_buy | Mean target | $52.75 |
| 52w high | $42.68 | 52w low | $26.05 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $8.9M | $6.6M | $10.9M | $208M | $0.0M | — |
| Op margin | -1380.7% | -1654.6% | -869.5% | 52.2% | — | — |
| Net income | -$112M | -$98.5M | -$83.3M | $119M | -$77.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$122M | -$109M | -$94.6M | $108M | -$88.8M | — |
- Revenue +35% vs prior quarter ($8.9M vs $6.6M).
- Operating margin expanded to -1380.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $219M | $7.0M | $23.4M | $50.9M | — |
| Op margin | -72.8% | -4671.1% | -574.9% | -122.7% | — |
| Net income | -$114M | -$274M | -$113M | -$58.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$159M | -$327M | -$134M | -$62.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · IDEAYA Biosciences (IDYA) Rethinks Its R And D Leadership As Undervaluation Questions Grow
2026-09-28 · IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
2026-09-28 · Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts
2026-09-25 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-25 · Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
2026-09-09 · Ideaya Biosciences, Servier Dose First Patient in Phase-3 Primary Uveal Melanoma Trial
2026-08-31 · Sector Update: Healthcare Stocks Fall Premarket Monday
2026-08-31 · IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy
2026-08-28 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns